Note to our followers: Our nearly 13-year run of daily publication of new content on came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years.

Following the dexamethasone COVID-19 drug news as it unfolds today

Posted By


Gary Schwitzer is the founder of and has been its publisher for 14 years. He has been a health care journalist for 47 years. He tweets as @garyschwitzer or as @HealthNewsRevu.

I’m flying solo while trying to catch up on today’s news on preliminary announcement of trial results of the drug dexamethasone for COVID-19 patients.

What follows is a series of tweets in response to what the Associated Press, CNN, the BBC, the New York Times, and some smart physicians on Twitter have written. Among the key points:

  • The trial results have not been peer-reviewed or published yet.
  • Some experts are hesitant to make conclusive statements until they can scour all of the data, which are not yet available.
  • One thing that is lacking in the early reports – much of it via PR news release – is any discussion of side effects from dexamethasone – a steroid drug.

This thread began when an old friend, a Minneapolis journalist, asked me to weigh in on CNN’s report about the drug trial.

You might also like


Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.